ImmunityBio says ANKTIVA plus BCG hits primary endpoint in BCG-naïve bladder cancer trial
The company said a supplemental BLA remains on track for year-end 2026 submission, with Q3 net product revenue up 53% to $48.7 million.
FDA, SEC filing (3)
2 stories
The company said a supplemental BLA remains on track for year-end 2026 submission, with Q3 net product revenue up 53% to $48.7 million.
FDA, SEC filing (3)
The agency approved the drug, marketed as Anktiva, for use with BCG in adults with BCG-unresponsive non-muscle invasive bladder cancer.
SEC filing, Drugs@FDA, FDA, FDA press release (4)